Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
I-MAK Profile picture
I-MAK
@IMAKglobal
A team of lawyers, scientists, and health experts challenging systemic injustice and advocating for health equity in drug development and access.
Cordovil Profile picture 1 subscribed
May 17, 2023 • 9 tweets • 3 min read
In our new report with @econliberties we examine the most widely-practiced strategies pharma employs to game the patent system to extend exclusivities and keep drug prices high.

🧵 on of those tactics ⬇️

Company: Indivior
Drug: Suboxone
Strategy: Product hopping

(1/9) Graphic features an image o... Suboxone is a prescription oral medication marketed by Indivior that minimizes withdrawal symptoms in patients recovering from opioid addiction. (2/9)
Dec 15, 2021 • 16 tweets • 9 min read
🧵 (1/16): Our key takeaways from the House Oversight Committee’s final report concluding its three-year investigation into the pharmaceutical industry’s anti-competitive pricing and business tactics. .@RepMaloney introduces the report with a letter to Committee Members. In it, she reviews what their nearly 3-year investigation revealed:

“Drug companies have raised prices relentlessly for decades while manipulating the patent system and other laws”
May 16, 2021 • 8 tweets • 2 min read
Right now, the list price for a year of treatment with Humira is $77k in the U.S. With the availability of biosimilars, the estimated annual price in the EU is $3.5k.

That’s a whopping 22x price difference.

A 🧵 on why the prices for the exact same drug are so different. AbbVie released Humira in 2002 as an anti-inflammatory treatment.

It raised the price steadily in both the EU & US until 2018, when Humira’s patent protection in Europe ended & biosimilar competitors could enter the market.

The result: W/in 4 months, Humira’s price dropped 70%.
May 14, 2021 • 6 tweets • 4 min read
Need to prepare for next week’s drug pricing hearing with AbbVie? Here’s a thread of four useful resources to read and listen to. ⤵️ “Protect at all costs: how the maker of the world’s bestselling drug keeps prices sky-high”

By @the_sy_guy - @FortuneMagazine
fortune.com/longform/abbvi…